Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Cadus Pharmaceutical Corp. (KDUS) -- Ignore unavailable to you. Want to Upgrade?

To: scaram(o)uche who wrote (583)	10/7/2001 9:07:22 PM
From: scaram(o)uche	Read Replies (1) \| Respond to of 1833

Mol Genet Genomics 2001 Aug;265(6):1120-8 Genetic selection in Saccharomyces of mutant mammalian adenylyl cyclases with elevated basal activities. Haney SA, Xu J, Lee SY, Ma CL, Duzic E, Broach JR, Manfredi JP. Cadus Pharmaceutical Corporation, Tarrytown, NY 10591, USA. We show that co-expression of rat Galphas together with type I, II, IV, or VI mammalian adenylyl cyclase (AC) can suppress the growth defect of cyr1 strains of Saccharomyces cerevisiae, which lack a functional endogenous AC. Complemention of cvr1 is not observed in the absence of Galphas, indicating that the mammalian ACs retain their normal regulatory behavior in yeast. Selection for Galphas-independent growth of (cyr1 strains expressing type IV AC yielded several ACIV mutants with enhanced basal activity, each of which had a single amino acid substitution in the conserved C1a or C2a region of the protein. Expression of two of the mutant ACs in HEK293 cells resulted in increased levels of cAMP and elevated adenylyl cyclase activity. Further selection for reverting mutations in one of these constitutively active AC mutants yielded three independent intragenic suppressor mutations. The distribution of the activating and suppressor mutations throughout both C1a and C2a is consistent with a model in which the enhanced basal activity results from an increase in the affinity between C1a and C2a. These results demonstrate the utility of Saccharomyces as a tool for the identification of informative mutant forms of mammalian ACs.

To: scaram(o)uche who wrote (583)	10/8/2001 1:00:21 AM
From: BulbaMan	Respond to of 1833

Rick: My notes indicate Biacore held 1,333,333 shares of Axiom. So, if Axiom is paying $3 million to repurchase 3/4 or 1 million of Biacore’s Axiom shares, you’ve got a $3 per share valuation for Axiom (exactly the amount Biacore paid per share in May, 2000, when it invested in Axiom). This puts the value of Cadus’ 2,109,161 shares at abot $6.2 million, a bit less than my earlier $7.35 million value. However, my guess is Axiom got a bargain price from Biacore and the per share value is definitely higher.